Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes

NCT02966782 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02966782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02966782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
March 7, 2017
Completion date
April 5, 2023
Enrollment
70 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes (mds)